ARTICLE | Finance
Swords to plowshares
How Ariad's outgoing Berger can profit from cancer company's progress
May 4, 2015 7:00 AM UTC
Sarissa Capital Management succeeded in prompting the retirement of Harvey Berger from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), but the outgoing chairman and CEO has a vested interest in the activist investor's ability to unlock value in the cancer company.
According to SEC filings, Berger directly held 1.3 million Ariad shares as of March 26 and indirectly held another 2.4 million shares as of Feb. 12, which translates to a total stake of about 2%. ...